TCR2 THERAPEUTICS INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2018 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tcr2 Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q1 2023.
  • Tcr2 Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2023 was $579K, a 81.8% decline year-over-year.
  • Tcr2 Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2023 was $8.78M, a 28.7% decline year-over-year.
  • Tcr2 Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11.4M, a 7.22% decline from 2021.
  • Tcr2 Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12.3M, a 44.4% increase from 2020.
  • Tcr2 Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2020 was $8.49M, a 26.7% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $8.78M $579K -$2.6M -81.8% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $11.4M $2.66M -$77K -2.81% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-23
Q3 2022 $11.5M $2.69M -$493K -15.5% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $12M $2.85M -$372K -11.6% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $12.3M $3.18M +$57K +1.83% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $12.3M $2.74M +$434K +18.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 $11.8M $3.19M +$1.12M +54.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $10.7M $3.22M +$1.16M +56% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $9.56M $3.12M +$1.07M +51.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $8.49M $2.31M +$201K +9.55% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 $8.29M $2.07M +$55K +2.73% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $8.24M $2.06M +$620K +42.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $7.62M $2.06M +$914K +80.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $6.7M $2.11M +$1.26M +150% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 $5.44M $2.01M +$1.36M +206% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $4.09M $1.44M +$1.09M +313% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $2.99M $1.14M +$858K +303% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $2.13M $843K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 $657K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $350K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $283K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.